Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Comment
. 2022 Mar 14;194(10):E390.
doi: 10.1503/cmaj.81278.

The authors respond to "Concerns about subgroup analyses and reason for stopping remdesivir trial"

Srinivas Murthy  1
Affiliations
Comment

The authors respond to "Concerns about subgroup analyses and reason for stopping remdesivir trial"

Srinivas Murthy. CMAJ. .
No abstract available

PubMed Disclaimer

Conflict of interest statement

Competing interests: None declared.

Comment on

  • Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial.
    Ali K, Azher T, Baqi M, Binnie A, Borgia S, Carrier FM, Cavayas YA, Chagnon N, Cheng MP, Conly J, Costiniuk C, Daley P, Daneman N, Douglas J, Downey C, Duan E, Duceppe E, Durand M, English S, Farjou G, Fera E, Fontela P, Fowler R, Fralick M, Geagea A, Grant J, Harrison LB, Havey T, Hoang H, Kelly LE, Keynan Y, Khwaja K, Klein G, Klein M, Kolan C, Kronfli N, Lamontagne F, Lau R, Fralick M, Lee TC, Lee N, Lim R, Longo S, Lostun A, MacIntyre E, Malhamé I, Mangof K, McGuinty M, Mergler S, Munan MP, Murthy S, O'Neil C, Ovakim D, Papenburg J, Parhar K, Parvathy SN, Patel C, Perez-Patrigeon S, Pinto R, Rajakumaran S, Rishu A, Roba-Oshin M, Rushton M, Saleem M, Salvadori M, Scherr K, Schwartz K, Semret M, Silverman M, Singh A, Sligl W, Smith S, Somayaji R, Tan DHS, Tobin S, Todd M, Tran TV, Tremblay A, Tsang J, Turgeon A, Vakil E, Weatherald J, Yansouni C, Zarychanski R; Canadian Treatments for COVID-19 (CATCO); Association of Medical Microbiology and Infectious Disease Canada (AMMI) Clinical Research Network and the Canadian Critical Care Trials Group. Ali K, et al. CMAJ. 2022 Feb 22;194(7):E242-E251. doi: 10.1503/cmaj.211698. Epub 2022 Jan 19. CMAJ. 2022. PMID: 35045989 Free PMC article. Clinical Trial.
  • Concerns about subgroup analyses and reason for stopping remdesivir trial.
    Vijayaraghavan BKT. Vijayaraghavan BKT. CMAJ. 2022 Mar 14;194(10):E389. doi: 10.1503/cmaj.81197. CMAJ. 2022. PMID: 35288412 Free PMC article. No abstract available.

References

    1. Vijayaraghavan BKT. Concerns about subgroup analyses and reason for stopping remdesivir trial [letter]. CMAJ 2022;194:E389. - PMC - PubMed
    1. Ali K, Azher T, Baqi M, et al. . Remdesivir for the treatment of patients in hospital with COVID-19 in Canada: a randomized controlled trial. CMAJ 2022;194:E242–51. - PMC - PubMed
    1. Beigel JH, Tomashek KM, Dodd LE, et al. . Remdesivir for the treatment of COVID-19 — final report. N Engl J Med 2020;383:1813–26. - PMC - PubMed

MeSH terms